Wednesday, July 6, 2022
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home SCIENCE NEWS Biology

Contrast-enhanced mammography vs. MRI: Neoadjuvant therapy response in breast cancer

June 22, 2022
in Biology
0
Share on FacebookShare on Twitter

Leesburg, VA, June 22, 2022—According to ARRS’ American Journal of Roentgenology (AJR), contrast-enhanced mammography (CEM) may be a useful alternative test for neoadjuvant therapy (NAT) response assessment in patients with breast cancer who are unable to undergo MRI.

41-year-old woman with invasive ductal carcinoma (G2, luminal B) of right breast

Credit: American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

Leesburg, VA, June 22, 2022—According to ARRS’ American Journal of Roentgenology (AJR), contrast-enhanced mammography (CEM) may be a useful alternative test for neoadjuvant therapy (NAT) response assessment in patients with breast cancer who are unable to undergo MRI.

“After NAT for breast cancer, CEM and MRI yielded comparable assessments of lesion size (both slightly overestimated vs pathology) and RECIST categories, and no significant difference in specificity for pathologic complete response,” wrote corresponding author Rubina Manuela Trimboli of IRCCS Humanitas Research Hospital in Milan, Italy. Noting that MRI had higher sensitivity for pathologic complete response, “delayed CEM acquisition may help detect residual ductal carcinoma in situ (DCIS).”

Trimboli and team’s prospective study included 51 patients (mean age, 46 years) with biopsy-proven breast cancer from May 2015 to April 2018, who were candidates for NAT. Patients underwent both CEM and MRI before, during, and after NAT: pre-NAT, mid-NAT, and post-NAT, respectively. Post-NAT CEM included a 6-minute delayed acquisition. One breast radiologist with experience in CEM reviewed CEM examinations; one breast radiologist with experience in MRI reviewed MRI examinations.

Compared with pathology, post-NAT CEM, MRI, and delayed CEM systematically overestimated residual tumor size by 0.8 mm, 1.9 mm, and 1.2 mm, respectively. For detecting pathologic complete response by post-NAT imaging, sensitivity and specificity were 81% and 83% for CEM, 100% and 86% for MRI, and 81% and 89% for delayed CEM.

“While MRI remains the preferred test for NAT monitoring,” the authors of this AJR article concluded, “the findings support CEM as a useful alternative when MRI is contraindicated or not tolerated.”


North America’s first radiological society, the American Roentgen Ray Society (ARRS) remains dedicated to the advancement of medicine through the profession of medical imaging and its allied sciences. An international forum for progress in radiology since the discovery of the x-ray, ARRS maintains its mission of improving health through a community committed to advancing knowledge and skills with the world’s longest continuously published radiology journal—American Journal of Roentgenology—the ARRS Annual Meeting, InPractice magazine, topical symposia, myriad multimedia educational materials, as well as awarding scholarships via The Roentgen Fund®.

MEDIA CONTACT:

Logan K. Young, PIO

44211 Slatestone Court

Leesburg, VA 20176

703-858-4332

[email protected]



Journal

American Journal of Roentgenology

DOI

10.2214/AJR.22.27756

Method of Research

Observational study

Subject of Research

People

Article Title

Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study

Article Publication Date

22-Jun-2022

Tags: breastcancerContrastenhancedmammographyMRINeoadjuvantresponsetherapy
Share26Tweet16Share4ShareSendShare
  • PAN protein domain

    Scientists discover cancer trigger that could spur targeted drug therapies

    77 shares
    Share 31 Tweet 19
  • COVID-19 fattens up our body’s cells to fuel its viral takeover

    103 shares
    Share 41 Tweet 26
  • New guidelines laid out to standardize swallowing fluoroscopy

    65 shares
    Share 26 Tweet 16
  • Physicists work to shrink microchips with first one-dimensional helium model system

    65 shares
    Share 26 Tweet 16
  • How bilingual brains work: Cross-language interplay and an integrated lexicon

    65 shares
    Share 26 Tweet 16
  • New research challenges long-held beliefs about limb regeneration

    65 shares
    Share 26 Tweet 16
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

COVID-19 fattens up our body’s cells to fuel its viral takeover

Scientists discover cancer trigger that could spur targeted drug therapies

nTIDE May 2022 COVID Update: Uncertainty about inflation tempers good news for people with disabilities

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 190 other subscribers

© 2022 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2022 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....